Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant

Transplantation

Volumn 99, Issue 4, 2015, Pages 841-847

  Papadopoulos Köhn, Angela ^a   Achterfeld, Anne ^a   Paul, Andreas ^b   Canbay, Ali ^a   Timm, Jörg ^b   Jochum, Christoph ^a   Gerken, Guido ^a   Herzer, Kerstin ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; CREATININE; ELTROMBOPAG; ERYTHROPOIETIN; FILGRASTIM; HEMOGLOBIN; PEGINTERFERON ALPHA; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; TACROLIMUS; TELAPREVIR; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON; OLIGOPEPTIDE;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LIMIT OF DETECTION; LIVER BIOPSY; LIVER DISEASE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; NEPHROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; REINFECTION; RELAPSE; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; ADVERSE EFFECTS; AGED; BLOOD; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; DRUG MONITORING; GENETICS; GERMANY; HEPACIVIRUS; LIVER CIRRHOSIS; MIDDLE AGED; PATHOGENICITY; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; GENOTYPE; GERMANY; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OLIGOPEPTIDES; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84929748444     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000399     Document Type: Article

References (27)

1. Vinaixa C, Rubin A, Aguilera V, et al. Recurrence of hepatitis C after liver transplantation. Ann Gastroenterol. 2013;26:304.
2. Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol. 2012;26:531.
3. Marks KM, Jacobson IM. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. Antivir Ther. 2012;17:1119.
4. Kawaoka T, Takahashi S, Tatsukawa Y, et al. Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res. 2014.
5. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents-a potentially lethal cocktail. Hepatology. 2011;54:3.
6. Coilly A, Roche B, Duclos-Vallee JC, et al. Management of HCV transplant patients with triple therapy. Liver Int. 2014;34(Suppl 1):46.
7. Rabie R, Mumtaz K, Renner EL. Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis. Liver Transplant. 2013;19:36.
8. Berenguer M, Aguilera V, San Juan F, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation. 2010;90:1204.
9. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417.
10. Werner CR, Franz C, Egetemeyr DP, et al. Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment. J Viral Hepat. 2014;21:333.
11. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014;60:78.
12. Nakagawa M, Sakamoto N, Enomoto N, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun. 2004;313:42.
13. Roos K, Gotthardt D, Giese T, et al. Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy. Liver Transplant. 2014.
14. Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011; 54:20.
15. Hezode C. Management of anaemia and other treatment complications. Dig Liver Dis. 2013;45(Suppl 5):S337.
16. Boglione L, De Nicolo A, Cusato J, et al. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. J Viral Hepat. 2014;21:260.
17. Pariente A, Remy AJ, Lesgourgues B, et al. Risk factors for severe anaemia during telaprevir-based triple therapy: is acquired renal dysfunction the missing link? Liver Int. 2014.
18. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014.
19. Belema M, Meanwell NA. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. J Med Chem. 2014.
20. Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Ther Adv Gastroenterol. 2014;7:131.
21. Manns MP, von Hahn T. Novel therapies for hepatitis C-one pill fits all? Nat Rev Drug Discov. 2013;12:595.
22. Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013;13:1601.
23. Reddy KR, Wirjosemito A, Pavri TM, et al. HCV therapy with daclatasvir, PEG-IFN, and RBV after boceprevir-based therapy failure post-liver transplantation in hyper-IgM syndrome. Transplantation. 2014;97:e47.
24. Feld JJ. The beginning of the end: what is the future of interferon therapy for chronic hepatitis C? Antiviral Res. 2014;105:32.
25. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals. Hepatology. 2014.
26. Hill A, Khoo S, Fortunak J, et al. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis. 2014;58:928.
27. Herzer K, Papadopoulos-Kohn A, Timm J, et al. HCV reinfection after liver transplantation-management and first experiences with telaprevir-based triple therapy. Dtsch Med Wochenschr. 2013;138:1759.